To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.

Also called NCT05331014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 155 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05331014
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05331014. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-15 (actual); primary completion 2022-11-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension
Condition
Dyslipidemia
Condition
Hypertension
Intervention (Drug)
LivaloVA
Intervention (Drug)
LivaloV
Intervention (Drug)
VA
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct05331014
Content hash
ec422fea5a2b21c2ea94e3d7dacfcc0d07cf2ffdc6242b361a2d9df74b9522bd